Gynesonics yesterday released 12 month results from the FDA investigational device exemption pivotal trial of its Sonata system intended for diagnostic intrauterine imaging and the transcervical treatment of symptomatic uterine fibroids. Results from the trial were published in the journal Obstetrics and Gynecology, the Redwood City, Calif.-based company said. The company’s flagship Sonata System is a […]
Gynesonics closes $75m financing round
Gynesonics said today that it closed a $75 million equity financing round to support its Sonata system intended for diagnostic intrauterine imaging and the transcervical treatment of symptomatic uterine fibroids. The round was led by Bain Capital Life Sciences and joined by all the Redwood City, Calif.-based company’s existing investors, including Abingworth, Advanced Technology Ventures, […]
Hologic CFO McMahon jumps ship to Agilent | Personnel Moves – August 1, 2018
Hologic (NSDQ:HOLX) said yesterday that its CFO Bob McMahon is leaving to take up a CFO role at Agilent Technologies. The Marlborough, Mass.-based company said that its current chief accounting officer Karleen Oberton has been lifted to CFO, effective today. “Bob has made tremendous contributions to Hologic over the last four years, and we wish him […]
Gynesonics touts pivotal IDE Sonata trial results
Gynesonics today released results from the pivotal FDA investigational device exemption cleared trial for its Sonata system designed for the incision-free treatment of uterine fibroids, touting a 99% freedom from surgical reintervention for heavy menstrual bleeding. The Redwood City, Calif.-based company’s Sonata trial is a prospective, longitudinal, multi-center trial exploring the safety and effectiveness of […]
Gynesonics submits 510(k) premarket notification for uterine fibroid treatment
Gynesonics announced that it has submitted its 510(k) Premarket Notification to the FDA for its Sonata System. The Sonata System is a uterus preserving, incision-free uterine fibroid treatment that was designed to treat fibroids transcervically with radiofrequency energy. “Submission of the 510(k) application is an important milestone for our company,” Chris Owens, president and CEO […]
Wright Medical COO, ex-Tornier CEO Mowry, steps down | Personnel Moves May 5, 2016
Wright Medical COO, ex-Tornier CEO Mowry, steps down Wright Medical (NSDQ:WMGI) said yesterday its exec veep and chief operating officer, and former Tornier (NSDQ:TRNX) CEO, David Mowry will be stepping down from the company on May 6 to pursue other opportunities. The company did not indicate who would take Mowry’s position. Read more
RIP medical device pioneer Alfred Mann | Personnel Moves
Alfred Mann, a medical device entrepreneur who helped develop several groundbreaking technologies, died yesterday at age 90, shortly after stepping down from a pair of companies he founded. Mann founded 17 companies over his 70-year career, in industries ranging from aerospace to medtech, according to the L.A. Times. After Johns Hopkins University researchers in 1969 […]
Gynesonics tops off $46m round
Gynesonics said the $2.9 million it just added to its coffers closed out a funding round totaling $46 million. The round was led by USP Group’s Novit Ventures and included Endeavour Vision, Abingworth, HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital. Redwood City, Calif.-based Gynesonics makes the Sonata radiofrequency ablation device […]
Gynesonics raises $43m
Gynesonics said today it raised $43 million in a new round of equity financing, with funds slated to aid the company’s operations and support its Sonata radiofrequency ablation device used to treat intrauterine fibroids. The Sonata system is minimally invasive and incision-free, using radiofrequency ablation guided by sonography and preserving the uterus, unlike hysterectomies which […]
Intarcia raises $225m to fund diabetes trial | Medtech funding for the week of April 27, 2015
Gynesonics raises $3m for VizAblate fibroid device
California’s Gynesonics reported raising $3 million in a new debt offering as it pursues development of its VizAblate fibroid treatment device.
MassDevice Network
@MassDevice
LinkedIn
YouTube